Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.7 PLN | +1.14% | +4.12% | -2.48% |
May. 14 | Mabion S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 16 | Mabion S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The opinion of analysts covering the stock has improved over the past four months.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- Most analysts agree on a negative opinion with regard to the stock. Indeed, the average consensus issues recommendations to underperform or sell.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-2.48% | 73.33M | - | ||
+20.12% | 126B | B+ | ||
+25.25% | 119B | B+ | ||
+25.56% | 27.95B | B | ||
-19.51% | 20.5B | B+ | ||
-14.36% | 17.12B | A- | ||
-15.63% | 16.1B | B | ||
-46.67% | 14.97B | A- | ||
+11.89% | 14.84B | C+ | ||
+57.74% | 14.38B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- MAB Stock
- Ratings Mabion S.A.